Nanotech risk survey
This article was originally published in The Tan Sheet
The German Federal Institute for Risk Assessment (BfR) is conducting an expert survey on the risk of nanotechnology, the agency announces Aug. 22. The expert survey will focus on nanotechnology in foods, cosmetics and consumer goods. About 100 experts will participate in the multi-phase qualitative forecasting survey discussing current and future applications of nanotechnology and the opportunities and risks for consumers, the agency says. "The objective is to identify already used or potentially usable nanomaterials, assign them to concrete applications and then draw conclusions on consumer exposure," the institute states. Toward the end of the year, BfR will stage a "Consumer Conference on Perception of Nanotechnology." A final report on the conference will be made available to industry, "main stakeholders in the political circles," public agencies, scientists and non-governmental organizations, according to the release. "Both projects will help to identify scientifically determined and emotionally perceived risks early on and to carry them over to the communication process," BfR President Andreas Hensel states...
You may also be interested in...
Cosmetics Europe Talks Microplastic: ECHA Frustrations, ‘Value Judgments’ And International Trade Uncertainty
The European Chemicals Agency's microplastic restriction proposal received committee backing in 2020 without changes sought by the cosmetics industry, which faces €15bn in projected costs and scarce alternatives at present. It may come down to EU Member States to decide whether the ECHA restriction proposal is proportionate in balancing environmental goals and socio-economic impacts.
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.